- Title
- At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
- Creators - without role
- Rm Flipo - Hôpital Roger SalengroA. Saraux - Lymphocytes B, Autoimmunité et ImmunothérapiesChristophe Hudry - Hôpital CochinC Gaujoux-Viala - Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415E Senbel - Rheumatology Office, Marseille FranceS Tropé - Andar, ParisE Zinovieva - Medical Department Nordic Pharma, ParisA Courbeyrette - Medical Department Nordic Pharma, ParisH Herman-Demars - Medical Department Nordic Pharma, Paris
- Conference
- ACR/ARHP Annual Meeting (Chicago, United States, 19/10/2018–24/10/2018)
- Series
- Arthritis Rheumatology
- Identifiers
- 99106407409311
- Academic Unit
- Université de Montpellier
- Language
- English
- Resource Type
- Conference poster
- Local Fields
- hal-01950293
Conference poster
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
Arthritis Rheumatology
ACR/ARHP Annual Meeting (Chicago, United States, 19/10/2018–24/10/2018)
Metrics
1 Record Views